Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus
Фаза 1/2
Завершено
NCT02472795
| Заболевание | Systemic Lupus Erythematosus |
|---|
| Фаза | Фаза 1/2 |
|---|
| Спонсор | Viatris Innovation GmbH |
|---|
| Статус | Завершено |
|---|
| Участники | 105 участн. |
|---|
| Вмешательство | Matching placebo, Cenerimod |
|---|
| Дата начала | 1.06.2015 |
|---|
| Дата завершения | 23.01.2017 |
|---|
| Публикация результатов | 26.02.2020 |
|---|
Кратко
International trial to evaluate the biological activity and safety of cenerimod (ACT-334441) in systemic lupus erythematosus (SLE) patients.
Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT)
Baseline to end-of-treatment (EOT) (up to 12 weeks) · 10^9 cells/L
| Cenerimod 0.5 mg (Part A) | -0.26 ± 0.48 10^9 cells/L |
|---|
| Cenerimod 1 mg (Part A) | -0.96 ± 0.68 10^9 cells/L |
|---|
| Cenerimod 2 mg (Part A) | -0.86 ± 0.61 10^9 cells/L |
|---|
| Cenerimod 4 mg (Part B) | -0.87 ± 1.24 10^9 cells/L |
|---|
| Matching Placebo | -0.33 ± 0.72 10^9 cells/L |
|---|
| p-value | 0.39 |
|---|
| Mean Difference (Final Values) | -0.17 (95% CI -0.56–0.22) |
|---|
Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment
Baseline, Week 2, Week 4, Week 8, Week 12, end-of-treatment Visit (up to 12 weeks) · 10^9 cells/L
| Cenerimod 0.5 mg (Part A) | 1.37 ± 0.52 10^9 cells/L |
|---|
| Cenerimod 1 mg (Part A) | 1.71 ± 0.82 10^9 cells/L |
|---|
| Cenerimod 2 mg (Part A) | 1.62 ± 0.75 10^9 cells/L |
|---|
| Cenerimod 4 mg (Part B) | 1.88 ± 0.77 10^9 cells/L |
|---|
| Matching Placebo | 1.65 ± 0.88 10^9 cells/L |
|---|
| Cenerimod 0.5 mg (Part A) | -0.13 ± 0.56 10^9 cells/L |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.